Industry Explorers Blaze On

  1. Taking A Fresh Approach To Finance At BMS 9/1/2023

    A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.

  2. Why It's Imperative To Improve Your Program Governance 9/1/2023

    Organizations developing pharmaceuticals must leverage a more flexible style of project management that adapts throughout the product life cycle and promotes cross-functional operations to accelerate speed to market, optimizing economic performance and patient access to care. Here are three paths pharma companies can take to improve their project management outputs.

  3. What Impact Is The Inflation Reduction Act Already Having On Biopharma Companies, And What More Can The Industry Do Going Forward? 9/1/2023

    See the answer from Stephen Rapundalo, president and CEO of MichBio.

  4. Successfully Launching Drugs In Europe On Time And On Budget 9/1/2023

    In this article, Margarida Duarte of Deciphera Pharmaceuticals shares insights from her recent experience with launching a new oncology drug in Europe.

  5. Leading With Authenticity 9/1/2023

    While in my last corporate job at a Fortune 100 company, I realized the kind of leader I would be; I would be me — authentic, kind, collaborative, purpose-driven, and empowering.

  6. Companies To Watch: Nido Biosciences 9/1/2023

    See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.

  7. Nurses: One Of Life Sciences' Most Valuable Assets 9/1/2023

    With many years of experience working in pharma/biopharma, Janice Nissen is convinced that more companies should be building and supporting a greater network of medical professionals within their organizations — with a specific focus on nurses.

  8. Benefits Of Clinical Development Outsourcing Models 9/1/2023

    ISR’s Clinical Development Outsourcing Models (5th Edition) report examines three outsourcing models commonly used in the clinical trial space. Respondents provided feedback on the benefits of each outsourcing strategy currently used at their company.

  9. Cell & Gene Therapies Manufacturing Market Outlook 8/1/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition) research participants were asked to select the cell and gene manufacturing activities their company would outsource to CDMOs in the next 18 months and in five years.

  10. In These Times Of Increasingly Unpredictable And Lurching Change, What Skills Will Separate Out Next-Gen CEOs? 8/1/2023

    See the answer from Fred Hassan, the managing director at Warburg Pincus.